Implantable Defibrillator market size was valued at $3,300.00 million in 2020, and is projected to reach $5,612.62 million by 2030, registering a CAGR of 5.3% from 2021 to 2030. An implantable defibrillator is an implantable electronic device, which is effective for the treatment of sudden cardiac arrest (SCA) as well as for arrhythmia. The device can be programmed to detect an abnormal heart rate and to deliver shocks as per requirement. Implantable defibrillators are used to prevent sudden death in patients who sustained atrial fibrillation or ventricular tachycardia. These devices are implanted inside patientโs body and perform defibrillation, pacing of heart, and cardioversion. Irregular heart rhythms that require ICD implant include bradycardia, ventricular tachycardia, and ventricular fibrillation.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
- Abbott
- Biotronik SE & Co. KG
- Boston Scientific Corporation
- Fukuda Denshi Co. Ltd.
- Imricor Medical Systems
- Koninklijke Philips N.V.
- Livanova Plc Company
- Medtronic Plc
- Microport Scientific Corporation
- Nohen Kohden Corporation
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/2091
Implantable defibrillators are used when the heartbeat is not normal and tries to return the heartbeat to normal. If the ICD has a pacemaker feature when the heartbeat is too slow, it works as a pacemaker and sends tiny electric signals to the heart. When the heartbeat is too fast or chaotic, it gives defibrillation shocks to stop the abnormal rhythm. It works 24 hours a day. New devices also provide pacing to electrically convert a sustained ventricular tachycardia (fast heart rhythm) and backup pacing if bradycardia (slow heart rhythm) occurs. They also offer a host of other sophisticated functions such as storage of detected arrhythmic events and the ability to perform electrophysiologic testing.
Implantable defibrillator devices that constantly monitor the heart rhythm and when it detects an abnormally fast heart rhythm, it delivers energy to the heart muscle. The S-ICDs is a completely extra thoracic device, which has recently received FDA approval for prevention of sudden cardiac death. One of the primary advantages of subcutaneous implantable cardioverter-defibrillators is the absence of wires within the heart and preservation of central venous circulation. This property of the equipment makes it a great alternative for children with congenital heart disease with no venous access who were inappropriate for transvenous ICD.
Globally, it has been observed that maximum causes of deaths are caused due to heart diseases. This surge in geriatric population and increase in prevalence of chronic health conditions such as cardiac arrhythmia, ventricular fibrillation, and pulseless ventricular tachycardia, growth in preference for S-ICDs, and rise in awareness among patients regarding implantable defibrillators are expected to drive the implantable defibrillators market growth. Moreover, exposure of new technologies and increase in adoption of implantable defibrillators are expected to lead to spontaneous growth of the defibrillator market.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/2091
Along with this, increase in population along with rise in mortality, owing to cardiac arrests and other heart disease provide ample opportunities for the implantable heart defibrillator market players to grow and flourish globally.
The industry progression is being further driven by ongoing technological advancements and novel product developments in the business space. For instance, Abbott in 2020 declared receiving an FDA nod for its next-gen Gallant ICD and cardiac resynchronization therapy defibrillator devices. As per company officials, the devices offer Bluetooth technology and new patient smartphone applications for enhanced remote monitoring.
The implantable defibrillators market is segmented on the basis of type and region. On the basis of type, the market is divided into transvenous implantable cardioverter-defibrillator (T-ICDs), subcutaneous implantable cardioverter defibrillators (S-ICDS), and cardiac resynchronization therapy defibrillator (CRT-D). The transvenous implantable cardioverter-defibrillator (T-ICDs) segment currently dominates the global Implantable Defibrillator market and this trend is anticipated to continue during the forecast period as T-ICDs are the most commonly used devices to treat heart disorders for higher precision and targeted functioning.
North America accounted for a majority of the global Implantable Defibrillators market share in 2020 and is anticipated to a rise in the incidence of sudden cardiac arrest (SCA), increase in the adoption of S-ICDs, high purchasing power, and availability of advanced healthcare facilities. However, Asia-Pacific is expected to witness considerable implantable defibrillators market growth during the forecast period due to its high population base, increasing disposable incomes, and improvement in patient awareness about ICD devices.
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- By type, the transvenous implantable cardioverter-defibrillator (T-ICDs) segment currently dominates the global Implantable Defibrillators market and this trend is anticipated to continue during the forecast period as T-ICDs are the most commonly used devices to treat heart disorders for higher precision and targeted functioning.ย
- On the basis of region, in 2020, North America dominated the market in 2020, owing to rise in the incidence of sudden cardiac arrest (SCA), increase in the adoption of S-ICDs, high purchasing power, and availability of advanced healthcare facilities. However, Asia-Pacific is expected to witness considerable implantable defibrillator market growth during the forecast period due to its high population base, increasing disposable incomes, and improvement in patient awareness about ICD devices.
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
